BioCryst製藥 BCRX 深 滬
已收盤 09-19 16:00:00 美东时间
8.15
+0.190
+2.39%
華盛通- 最 高8.30
- 今 開8.17
- 成交量 192.50万股
- 最 低 8.00
- 昨 收 7.96
- 總市值 16.79亿
- 52周最高 8.88
- 市盈率 靜 --
- 換手率 0.93%
- 52周最低 4.03
- 委 比 -38.84%
- 總股本 2.06亿
- 歷史最高 19.99
- 量 比 1.34
- 振 幅 3.77%
- 歷史最低 1.08
- 每 手 1
- 風險率 1.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioCryst Presents Results on HAE Treatment and Patient Care at Global Symposium
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of six posters, including the first interim real-word evidence from the APeX-N trial, and new data highlighting the value of shared
09-06 15:02
BioCryst Pharmaceuticals names Donald Fong as chief medical officer
BioCryst Pharmaceuticals (NASDAQ:BCRX) said it has appointed Donald Fong as its new chief medical officer, effective immediately. Fong had joined the company in April 2024 as vice president of the oph...
09-05 19:17
‘Bottom-fishing’ ideas within Piper Sandler’s universe of stocks
Piper Sandler analysts selected 20 stocks that are "bottom-fishing" ideas. These stocks have had technical grade rankings of 20 for at least the last trailing five weeks, but with this week’s ranking ...
08-20 23:56
Piper lists eight defensive biotechs to face market volatility
With market volatility becoming a common phenomenon, Piper Sandler showcased eight "high-quality" defensive growth stocks in the biopharma space this week. Its comments came after a global sell-off of...
08-11 02:29
BioCryst制药盘中异动 大幅下挫5.21%
北京时间2024年08月08日00时01分，BioCryst制药（BCRX.us）股票出现波动，股价快速下跌5.21%。截至发稿，该股报7.46美元/股，成交量...
08-08 00:01
RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $10 Price Target
RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:BCRX) with a Outperform and maintains $10 price target.
08-06 20:34
BioCryst up 8% after raising 2024 Orladeyo revenue guidance
BioCryst Pharmaceuticals (NASDAQ:BCRX) is up ~8% Monday after increasing its full-year outlook for its hereditary angioedema treatment Orladeyo (berotralstat). The company now sees $420M-$435M, up fro...
08-06 03:55
Orladeyo’s Robust Sales Growth Fuels BioCryst’s Buy Rating and Raised Price Target
Needham analyst Serge Belanger has maintained their bullish stance on BCRX stoc...
08-06 02:15
There's No Escaping BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Muted Revenues
You may think that with a price-to-sales (or "P/S") ratio of 4.2x BioCryst Phar...
07-15 18:10
喜报｜帕拉米韦注射液获得《药品注册证书》
7月3日，华润双鹤发布公告，旗下子公司京西双鹤的帕拉米韦注射液获得国家药监局《药品注册证书》(证书编号：2024S01353)。根据国家相关政策规定，本次获得...
07-03 16:54
